Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx ...

Update 1:25pm: Adds Jefferies analyst comment. Exelixis (NASDAQ:EXEL) rose 5% as the patent trial over its Cabometyx drug ended. Closing arguments took place in a Delaware court on Thursday ...

Exelixis is pursuing an additional approval for Cabometyx in neuroendocrine tumors. The U.S. FDA has assigned an action date ...

Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar. The FDA has ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claim of the '349 patent not infringed and not invalid ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A ...